Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma
Elana Thieme, Nur Bruss, Duanchen Sun, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 21

Showing 21 citing articles:

Super enhancer lncRNAs: a novel hallmark in cancer
Ping Song, Rongyan Han, Fan Yang
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Shenglan Liu, Wei Dai, Bei Jin, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 7
Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application
Yang Chen, Rui Liang, Yong Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Super-enhancers in hepatocellular carcinoma: regulatory mechanism and therapeutic targets
Xuejin Lu, Meizi Zhu, Xueliang Pei, et al.
Cancer Cell International (2025) Vol. 25, Iss. 1
Open Access
Targeting protein synthesis pathways in MYC-amplified medulloblastoma
Devendra Kumar, Ranjana Kanchan, Nagendra K. Chaturvedi
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Super-enhancers in tumors: unraveling recent advances in their role in Oncogenesis and the emergence of targeted therapies
Yu‐meng Ji, Baixue Li, Rongjin Lin, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
The mediator subunit complex protein MED15 promotes lipid deposition and cancer progression during hypoxia
Boqi Zhang, Yu Zhu, Yanfei Tang, et al.
Journal of Biological Chemistry (2025), pp. 108296-108296
Open Access
CDK9 degradation Inhibits Gastroesophageal Cancer growth and Overcomes Radiation Resistance by Increasing Chromatin Accessibility and Downregulating YAP1/TEAD signaling
Yanting Zhang, Mikel Ghelfi, Xue Yu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
MYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor – a preliminary analysis
Alison Rutz, Kennedee Weber, Aidan Forberg, et al.
Annals of Hematology (2025)
Open Access
Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy
Tizhi Wu, Zhiming Zhang, Guangyue Gong, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115774-115774
Closed Access | Times Cited: 9
Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential
Yu Zhang, Xiangxiang Zhou
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116667-116667
Open Access | Times Cited: 3
Mapping the dynamics of epigenetic adaptation in S. pombe during heterochromatin misregulation
Ajay Larkin, Colin Kunze, Melissa Seman, et al.
Developmental Cell (2024) Vol. 59, Iss. 16, pp. 2222-2238.e4
Closed Access | Times Cited: 2
Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy
Yue Lang, Yanan Lyu, Yehui Tan, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Selective inhibition of CDK9 in triple negative breast cancer
Ebtihal Mustafa, Geraldine Laven‐Law, Zoya Kikhtyak, et al.
Oncogene (2023) Vol. 43, Iss. 3, pp. 202-215
Open Access | Times Cited: 5
Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS‐mutant Cancers
Yafang Wang, Lansong Xu, Lijun Ling, et al.
Advanced Science (2024)
Open Access | Times Cited: 1
CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma
Chen‐Hui Luo, Lihong Hu, Jie-Yang Liu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription
Melanie M. Frigault, Arushi Mithal, Harvey Wong, et al.
Cancer Research Communications (2023) Vol. 3, Iss. 11, pp. 2268-2279
Open Access | Times Cited: 2
Identification of Immune-Related Gene Pair Signature to Predict Prognosis of Diffuse Large B-Cell Lymphoma Based on Bioinformatics Analyses
Zeinab Davoodi‐Moghaddam, Farideh Jafari‐Raddani, Davood Bashash
Cancer Investigation (2024), pp. 1-18
Closed Access
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Matthew S. Davids, Danielle M. Brander, Yesid Alvarado, et al.
Blood Advances (2024)
Open Access
Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications
Edward C. Dominguez, Carly Roleder, Brian Ball, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 12, pp. 1893-1904
Closed Access | Times Cited: 1
Mapping the dynamics of epigenetic adaptation during heterochromatin misregulation
Ajay Larkin, Colin Kunze, Melissa Seman, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top